# FDA 483 - Instituto Grifols, S.A. - November 17, 2023

Source: https://www.keypedia.com/records/483/instituto-grifols-sa/aa26f7fe-87f5-4896-8bf9-06b32f81d0aa

> FDA 483 for Instituto Grifols, S.A. on November 17, 2023. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Instituto Grifols, S.A.
- Inspection Date: 2023-11-17
- Product Type: biologics
- Office Name: Division of Blood Components and Devices
- Summary: Instituto Grifols, S.A. in Parets Del Valles, Barcelona, Spain, was cited for significant deficiencies in its quality control and complaint handling systems. The inspection revealed inadequate investigations into product quality complaints and unexplained discrepancies, as well as failures in following and establishing proper procedures for production, process controls, and stability testing. These issues indicate a systemic breakdown in ensuring drug product quality and integrity.

## Related Documents

- [483 - Unknown Date](https://www.keypedia.com/records/483/instituto-grifols-sa/4939d8ab-7d38-4600-a6f3-933122f8dc31)
- [483 - 2023-11-17](https://www.keypedia.com/records/483/instituto-grifols-sa/98a4876f-4fd1-47c1-9c57-bae31b325cd6)

## Related Officers

- [investigator](https://www.keypedia.com/people/susan-m-jackson/2a4e01d1-8761-4d40-b493-69a4163473bb)
- [Shafiq Ahadi](https://www.keypedia.com/people/shafiq-ahadi/593bbf28-02e6-47bb-86c3-65cbd4ec520d)
- [Natalya M Ananyeva](https://www.keypedia.com/people/natalya-m-ananyeva/7469eb4d-fba3-4af6-a4d9-119934f82a41)
- [Sergey S. Akimov](https://www.keypedia.com/people/sergey-s-akimov/4eca8d78-ef17-49a7-aaa1-5fa8fecf0383)

Company: https://www.keypedia.com/companies/instituto-grifols-sa/478ef862-9ed8-4172-919f-c7475c316b61

Office: https://www.keypedia.com/offices/division-of-blood-components-and-devices/02cc5ccf-d21e-445f-91e7-474736bc8917